Hitachi Chemical to develop additional applications for MAST IVD technology following acquisition.
This article was originally published in The Gray Sheet
Executive Summary
HITACHI'S $30 MIL. BUY OF REMAINING MAST IMMUNOSYSTEMS STAKE gives the Tokyo, Japan-based conglomerate complete ownership of in vitro diagnostic manufacturer MAST. The companies announced Nov. 4 the signing of a definitive agreement under which Hitachi Chemical would purchase the roughly 75% stake of MAST that it does not currently own in a cash transaction expected to close by the end of 1996.